CRLHealthcare · Diagnostics & ResearchThe 16 Wall Street analysts covering Charles River Laboratories International, Inc. hold a median 12-month price target of $300 — +4.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 5 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Charles River Laboratories International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (53): The share price moves around a lot.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CRL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +4.0% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | TD Cowen | Maintains | Buy | $235 → $300 |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | $260 → $300 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $260 → $300 |
| 6 Aug 2026 | JP Morgan | Upgrade | Overweight | $180 → $310 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $215 → $282 |
| 20 July 2026 | CLSA | Downgrade | Hold | $219 |
| 20 July 2026 | CLSA | Downgrade | Hold | — |
| 13 July 2026 | Mizuho | Maintains | Neutral | $192 → $230 |
| 13 July 2026 | Mizuho | Maintains | Neutral | — |
| 9 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 9 July 2026 | Morgan Stanley | Maintains | Overweight | $220 → $260 |
| 17 June 2026 | Morgan Stanley | Upgrade | Overweight | — |
| 29 May 2026 | CLSA | Upgrade | Outperform | — |
| 8 May 2026 | Barclays | Maintains | Overweight | — |
| 8 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 13 Apr 2026 | JP Morgan | Maintains | Neutral | — |
| 25 Feb 2026 | UBS | Maintains | Neutral | — |
| 20 Feb 2026 | Mizuho | Maintains | Neutral | — |
| 20 Feb 2026 | TD Cowen | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Charles River Laboratories International, Inc. returned +77.7% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 37% of US stocks
Cheaper than 22% of US stocks
Cheaper than 16% of US stocks
Higher than 23% of US stocks
Higher than 33% of US stocks
Higher than 44% of US stocks
Higher than 73% of US stocks
Higher than 23% of US stocks
Higher than 37% of US stocks
Higher than 71% of US stocks
Higher than 7% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Charles River Laboratories International, Inc. has a market value of $13.9B and an enterprise value of $16.7B.
Revenue in the twelve months to 30 June 2026: $4.0B. The latest quarter shrank 2.7% year on year.
Net income over the same four quarters: −$236.3M, a −5.9% net margin.
Diluted earnings per share, trailing twelve months: $−4.85.
Free cash flow in the twelve months to 30 June 2026: $370.6M, after $211.5M of capital spending.
Charles River Laboratories International, Inc. spent $324.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 681.3×; forward P/E: 22.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.42%, paying out 0% of earnings.
Charles River Laboratories International, Inc. employs 18,300 people — $219K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Charles River Laboratories International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Charles River Laboratories reported earnings 30 days ago, and its stock has risen 10.5% since that report. The article examines whether the stock can sustain this upward momentum going forward.
Why it matters — CRL watchers would care because the piece assesses the sustainability of the stock's recent post-earnings gains, offering perspective on its near-term trajectory.
A Zacks Investment Research article examines whether it is the right time to add Charles River Laboratories (CRL) stock to a portfolio, noting that improving DSA demand and strategic investments support growth while uneven recovery and NHP cost volatility remain key risks.
Why it matters — CRL watchers would care because the piece highlights the balance between growth drivers and cost and demand risks affecting the company's outlook.
Prediction markets indicate the Clarity Act is unlikely to pass until mid-2027 at the earliest, and if it stalls in Congress, the crypto industry would depend on favorable rule making from agencies such as the SEC, CFTC, and OCC.
Why it matters — A CRL watcher would care because the timing and outcome of crypto regulatory legislation could influence the broader financial and regulatory environment in which the company operates.
Charles River Laboratories' stock rose 33.3% over the past month, driven by stronger bookings and guidance, though the rally now faces margin pressure and a premium valuation.
Why it matters — A CRL watcher would care because the recent surge raises the question of whether the stock's momentum can be sustained given the competing factors of improved bookings and cost pressures.
Charles River Laboratories shares have risen 88.6% over the past year, driven by Discovery and Safety Assessment returning to organic growth, rising bookings, and new testing initiatives that broaden the company's strategy.
Why it matters — CRL watchers would care because the stock's strong year-over-year performance reflects renewed organic growth and strategic expansion in its testing business.
The 16 Wall Street analysts covering Charles River Laboratories International, Inc. have a median 12-month price target of $300, with estimates ranging from $145 to $318. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Charles River Laboratories International, Inc., 13 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Charles River Laboratories International, Inc. 84 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Sept 2026, Charles River Laboratories International, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +4.0% from the last close, and Ticker Nerd's factor model ranks Charles River Laboratories International, Inc. 84 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Charles River Laboratories International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $318 over the next 12 months.
Charles River Laboratories International, Inc. returned +77.7% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Charles River Laboratories International, Inc. is a global drug development services company that supports pharmaceutical, biotechnology, and medical device organizations across the research and preclinical stages.
The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?". Charles River Laboratories reported earnings 30 days ago, and its stock has risen 10.5% since that report. The article examines whether the stock can sustain this upward momentum going forward.
Charles River Laboratories International, Inc. is a global drug development services company that supports pharmaceutical, biotechnology, and medical device organizations across the research and preclinical stages. Charles River Laboratories provides research models, discovery services, non-clinical safety assessment, and manufacturing-related testing solutions that help clients evaluate new therapies and products before clinical use. Its business spans three main segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The company also offers specialized support for biologics, microbial testing, endotoxin testing, and cell-based research, serving customers in life sciences, academia, and government research. Headquartered in Wilmington, Massachusetts, Charles River Laboratories plays a key role in the outsourced research and development ecosystem by supplying the tools, services, and scientific expertise used to advance drug discovery and product safety worldwide.
CEO Ms. Birgit Girshick · 18,300 employees · United States · https://www.criver.com
